Dukes Prevents Class Cert. In Nexium MDL, AstraZeneca Says

Law360, New York (September 17, 2013, 2:40 PM EDT) -- AstraZeneca PLC and several generic-drug makers facing multidistrict antitrust litigation alleging they unlawfully delayed the market entry of a generic form of Nexium told a Massachusetts federal judge Monday that a "sprawling class" of the drug's third-party purchasers should not be certified in light of the Supreme Court's Wal-Mart Stores Inc. v. Dukes decision.

The drug companies, AstraZeneca, Ranbaxy Inc., Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. — which were hit with the suits over pay-for-delay settlements they had reached putting off the introduction...
To view the full article, register now.